Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 14 (4) |
| Completed vs Stopped Early | 1 / 1 (6.3%) |
| Median Closed Actual Enrollment | 73 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hôpital Saint-Antoine | Paris | 12 |
| CHU Poitiers | Poitiers, New Aquitaine | 11 |
| Centre Léon Bérard | Lyon | 7 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06253611 | First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer | Phase II | RECRUITING |
| NCT06059495 | DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the GERCOR - Multidisciplinary Oncology Cooperative Group Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.